首页> 外文期刊>Biomolecular engineering >RNA interference in cancer
【24h】

RNA interference in cancer

机译:RNA干扰癌症

获取原文
获取原文并翻译 | 示例
       

摘要

In the recent years, RNA interference (RNAi) has emerged as a major regulatory mechanism in eukaryotic gene expression. The realization that changes in the levels of microRNAs are directly associated with cancer led to the recognition of a new class of tumor suppressors and oncogenes. Moreover, RNAi has been turned into a potent tool for artificially modulating gene expression through the introduction of short interfering RNAs. A plethora of individual inhibitory RNAs as well as several large collections of these reagents have been generated. The systems for stable and regulated expression of these molecules emerged as well. These tools have helped to delineate the roles of various cellular factors in oncogenesis and tumor suppression and laid the foundation for new approaches in gene discovery. Furthermore, successful inhibition of tumor cell growth by RNAi aimed at oncogenes in vitro and in vivo supports the enthusiasm for potential therapeutic applications of this technique. In this article we review the evidence of microRNA involvement in cancer, the use of short interfering RNAs in forward and reverse genetics of this disease, and as well as both the benefits and limitations of experimental RNAi. (C) 2006 Elsevier B.V. All rights reserved.
机译:近年来,RNA干扰(RNAi)已成为真核基因表达中的主要调控机制。 microRNA水平的变化与癌症直接相关的认识导致人们认识到一类新型的肿瘤抑制基因和致癌基因。此外,RNAi已成为通过引入短干扰RNA人工调节基因表达的有效工具。已经产生了大量的单个抑制性RNA以及这些试剂的多个大集合。也出现了用于稳定和调节这些分子表达的系统。这些工具有助于描述各种细胞因子在肿瘤发生和肿瘤抑制中的作用,并为基因发现的新方法奠定了基础。此外,针对体内和体外致癌基因的RNAi对肿瘤细胞生长的成功抑制支持了对该技术的潜在治疗应用的热情。在本文中,我们回顾了微小RNA参与癌症,在这种疾病的正向和反向遗传学中使用短干扰RNA的证据,以及实验性RNAi的益处和局限性。 (C)2006 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号